Work

Immune checkpoint inhibitor–induced inflammatory arthritis as a model of autoimmune arthritis

Year: 2020

Type: review

Abstract: The development of inflammatory arthritis in patients receiving immune checkpoint inhibitor therapy is increasingly recognized due to the growing use of these drugs for the treatment of cancer. This represents an important opportunity not only to define the mechanisms responsible for the development of this immune-related adverse event and to ultimately predict or prevent its development, but also to provide a unique window into early events in the development of inflammatory arthritis. Knowledge gained through the study of this patient population, for which the inciting event is known, could shed light into the pathogenesis of autoimmune arthritis. This review will highlight the clinical and immunologic features of these entities to define common elements for future study.

Source: Immunological Reviews

DOI: 10.1111/imr.12832

Authors: Laura C. Cappelli, Mekha A. Thomas, Clifton O. Bingham, Ami A. Shah, Erika Darrah

Institutions: Johns Hopkins University, Johns Hopkins Medicine

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Bristol-Myers Squibb, Rheumatology Research Foundation, National Institute of Arthritis and Musculoskeletal and Skin Diseases